Garay, Osvaldo Ulises
Nishimwe, Marie Libérée
Bousmah, Marwân-al-Qays
Janah, Asmaa
Girard, Pierre-Marie
Chêne, Geneviève
Moinot, Laetitia
Sagaon-Teyssier, Luis
Meynard, Jean-Luc
Spire, Bruno
Boyer, Sylvie http://orcid.org/0000-0002-7567-5200
Funding for this research was provided by:
Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS 140)
Article History
First Online: 9 April 2019
Compliance with Ethical Standards
:
: This study was sponsored and funded by the French National Institute for Health and Medical Research–France Recherche Nord&Sud Sida-HIV Hepatites (Inserm-ANRS), Paris, France. ANRS 140 DREAM trial was conducted with the support of AbbVie, Bristol-Myers Squibb and Gilead Science.
: BS received fees from Merck Sharp and Dohme, Gilead and Jansen-Cilag for seminars and participation in scientific boards of observational studies. OUG, MLN, MQB, AJ, P-MG, GC, LM, LST, J-LM and SB have no conflicts of interest that are directly relevant to the content of this article.
: The protocol was approved by the ethics committee “Comité de Protection des Personnes Ile de France V, Paris, France” and the French competent health authority (Agence nationale de sécurité du médicament et produits de santé).
: All study participants provided written informed consent. The trial was conducted in accordance with the Declaration of Helsinki.